MAP2K7 and melanoma: In BRAFV600‐mutant melanoma, treatment with combined BRAF and MEK inhibitors (BRAF/MEKi) yields high initial response rates and is a standard‐of‐care therapy.[6] However, resistance inevitably develops in nearly all patients, with a median duration of response of only 10.5 months.[7, 8] Most strategies to counteract resistance have focused on cell‐intrinsic mechanisms, particularly MAPK pathway reactivation, yet no such approaches have achieved clinical approval.